11 June 2021
BerGenBio ASA: Increase of share capital, exercise of share options and disclosure of trade by primary insider
Bergen, Norway, 11 June 2021
The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, today resolved to increase the Company’s share capital by NOK 7,500 by issuance of 75,000 new shares. The new shares are subscribed for by option owner who wishes and are entitled to exercise options in accordance with the Company’s option scheme. Each option gives a right to receive one share in the Company. The subscription price is in accordance with the prevailing options price pursuant to the Company’s option scheme NOK 10.62 per share.
The 75,000 options are exercised by primary insider Richard Godfrey (CEO) and the options are granted 13 June 2013 and expiry on 13 June 2021. Primary insider notification pursuant to the market abuse regulation article 19 is attached.
The primary insider has transferred his rights to receive shares resulting from the exercise of options to a third party. The third party has sold the shares at a price of NOK 25.67 per share.
Following the exercise, primary insider Richard Godfrey are holding 1,684,978 options in the Company of which 1,096,462 is vested, in addition to 21,005 shares in the Company through Gnist Holding AS.
The capital increase is expected to be registered within 7 days, and following the issuance of the new shares, the issued share capital of BerGenBio ASA will be NOK 8,796,275.50 consisting of 87,962,755 shares, each with a par value of NOK 0.10.
-End-
Contacts
Richard Godfrey
CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
